v3.26.1
Equity-Accounted Investees and Joint Business - Grifols Egypt for Plasma Derivatives (S.A.E.) and Shanghai RAAS Blood Products Co. Ltd (Details)
¥ in Millions
12 Months Ended 60 Months Ended
Jul. 29, 2021
EUR (€)
Jul. 29, 2021
USD ($)
item
Dec. 31, 2028
USD ($)
Dec. 31, 2027
USD ($)
Dec. 31, 2026
USD ($)
Dec. 31, 2025
EUR (€)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
CNY (¥)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2025
USD ($)
Equity-Accounted Investees and Joint Business                          
Share capital           € 119,603,705   € 119,603,705          
Group companies, associates and business units               1,564,000,000          
Non-controlling interests                          
Equity-Accounted Investees and Joint Business                          
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity           € (110,000,000)   € 484,000,000          
SRAAS                          
Equity-Accounted Investees and Joint Business                          
Proportion of ownership interests in former associate after partial sale               6.58%          
SRAAS                          
Equity-Accounted Investees and Joint Business                          
Percentage of sales               20.00% 20.00% 20.00%      
Equity increases from loss of indirect ownership interest in GDS               € 508,000,000          
Grifols Egypt Plasma Derivatives S.A.E.                          
Equity-Accounted Investees and Joint Business                          
Number of plasma centers to be constructed | $   20                      
Contribution made € 30,000,000 $ 37,000,000         $ 22,000,000   $ 44,000,000   $ 22,000,000 $ 22,000,000 $ 147,000,000
Percentage of shareholding 49.00% 49.00%       49.00% 49.00% 49.00% 49.00% 49.00%      
Share capital | $   $ 300,000,000                      
Percentage of capital increase           49.00% 49.00%            
Total contributions | $                         $ 300,000,000
Grifols Egypt Plasma Derivatives S.A.E. | Forecast                          
Equity-Accounted Investees and Joint Business                          
Contribution made | $     $ 15,000,000 $ 39,000,000 $ 44,000,000                
SRAAS                          
Equity-Accounted Investees and Joint Business                          
Percentage of sales           20.00% 20.00% 20.00% 20.00% 20.00%      
Group companies, associates and business units               € 1,564,000,000          
Amount of fund received               1,560,000,000          
Recognizing a foreign exchange               18,000,000          
Financial gain from the derivative | ¥                   ¥ 13      
SRAAS | Grifols Diagnostics Solutions, Inc. | Non-controlling interests                          
Equity-Accounted Investees and Joint Business                          
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity               € 508,000,000          
National Service Projects Organization (NSPO) | Grifols Egypt Plasma Derivatives S.A.E.                          
Equity-Accounted Investees and Joint Business                          
Percentage of shareholding 51.00% 51.00%                      
Grifols Egypt                          
Equity-Accounted Investees and Joint Business                          
Number of plasma centers to be constructed | item   20                      
Percentage of ownership in joint venture 49.00% 49.00%                      
Grifols Egypt | National Service Projects Organization (NSPO)                          
Equity-Accounted Investees and Joint Business                          
Percentage of ownership in joint venture 51.00% 51.00%